Sentences with phrase «flt3 kinase inhibitor»

In contrast, HPV - inactive tumors often have mutations in the PIK3CA / PTEN / AKT pathway, indicating that AKT kinase inhibitors may be effective treatment options for these patients.»

An approach often used in treating CML is to block the Bcr - Abl activity using tyrosine kinase inhibitors (TKIs).

«We've crossed the Rubicon with respect to kinase inhibitors,» he says.

Overall, the results from oral kinase inhibitors are very exciting, says Robinson.

And none of these kinase inhibitors have yet been rigorously tested in a head - to - head comparison with the protein therapies already on the market.

The estimation of EGFR mutation status is essential for the identification of non-small cell lung carcinoma (NSCLC) patients who may benefit from treatment with EGFR tyrosine kinase inhibitors (TKIs), and hence for improving therapeutic efficacy.

These studies will investigate whether Src kinase inhibitors are best used in the adjuvant setting post-surgery or after chemotherapy to prevent the formation of local and distant disease recurrence.

However, advances in therapy have been made, notably the emergence of kinase inhibitors for patients whose disease relapsed, according to the study background.

Researchers found that genetically disrupting this pathway, or using the FDA - approved Src kinase inhibitor dasatinib, increases PUMA levels and decreases tumor progression and metastasis in mice by up to fivefold.

In the study, the authors suggest that using Src kinase inhibitors may be more effectively used as adjuvant therapies to block αvβ3 signaling and prevent disease spread.

For example, epidermal growth factor (EGFR) mutations may result in sensitivity to drugs that are EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib or gefitinib, whereas individuals with the EGFR T790M mutation are more resistant to these drugs.

Often such trials include genetic markers for drugs that target particular pathways, such as a kinase inhibitor for cancer treatment.

EGFR tyrosine kinase inhibitor (TKI) therapy is approved for EGFR activating mutation positive patients with advanced NSCLC, but the standard for determining mutation status is with DNA derived directly from tumor tissue, which can be limited or not available.

Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA.

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for patients with advanced non-small cell lung cancer (NSCLC) who have mutations in the EGFR gene.

Vemurafenib joins other multi-targeted kinase inhibitors (MKIs)(sorafenib, lenvatinib) shown to be effective in this patient population; in spite of responses to these drugs, the responses are temporary and additional treatment options are needed.

Pazopanib is a known tyrosine kinase inhibitor.

(Moussa is listed as an inventor on a patent application that Georgetown University filed related to nilotinib and the use of other tyrosine kinase inhibitors for the treatment of neurodegenerative diseases.)

This finding is the latest from Georgetown University Medical Center's Translational Neurotherapeutics Program (TNP) examining tyrosine kinase inhibitors in the treatment of neurodegenerative diseases.

DDRs inhibition with a tyrosine kinase inhibitor appears to insulate the brain via blood - brain barrier repair, which prevents harmful immune cells that circulate in the body from getting into the brain where they can indiscriminately attack and kill healthy and sick neurons, like those that have been unable to perform autophagy to «take out their trash,» says Moussa.

Pao was involved in studies of EGFR tyrosine - kinase inhibitors while at MSKCC, where he trained in medical oncology.

The next step for CNIO, which has been running a drug - discovery program since 2005, would be to look for c - RAF kinase inhibitors as potential cancer drugs.

PKIS2 is a collection of more than 500 kinase inhibitors donated by GSK, Pfizer and Takeda Pharmaceuticals that SGC - UNC makes available to the scientific community.

While more than 30 kinase inhibitors have been approved for the treatment of disease, the kinome has been largely unexplored until SGC - UNC, DiscoverX and other SGC partner companies embarked on this project.

Approximately 10 - 15 % of Caucasian and 30 - 35 % of Asian patients with NSCLC have a mutation in the epidermal growth factor receptor (EGFR), which can be successfully targeted with EGFR inhibitors called tyrosine kinase inhibitors (TKI), such as erlotinib, gefitinib and afatinib.

THE STUDIES A trilogy of papers published in the September 28 issue of Nature examine the role of a protein — cyclin - dependent kinase inhibitor p16INK4a — in aging, healing, and cancer.

«Through our collaboration with DiscoverX, we screened a large set of compounds that we call Published Kinase Inhibitor Set 2, and these results allowed us to reach the halfway point in constructing the KCGS» said David Drewry, a research associate professor at the UNC Eshelman School of Pharmacy and SGC - UNC principal investigator who is leading the project to develop the Kinase Chemogenomic Set.

The drug is a multi - kinase inhibitor (MKI)-- meaning it targets the specific enzymes that are required for growth in DTC.

If this is true, then immunocheckpoint blockade combination with EGFR tyrosine kinase inhibitors is a major path towards improving outcome of patients who have EGFR - mutant non-small-cell lung cancer.»

The presence of a germline EGFR T790M mutation also predicts for resistance to standard tyrosine kinase inhibitors (TKIs), which adds complexity to treatment.

An international research group has now shown that there is another, equally effective oral treatment option: the combination of methotrexate and the chemically synthesised Janus Kinase Inhibitor tofacitinib.

This visual abstract depicts how Wei et al. utilize single - cell phosphoproteomic analysis of patient derived glioblastoma models to identify shifts in signaling coordination following short - term treatment with kinase inhibitors, which facilitates the design of combination therapy approaches with reduced resistance and improved efficacy.

Drugs called tyrosine kinase inhibitors (TKIs) are generally successful at controlling the cancer.

«They also suggest that interactions between oncologic kinases and SYK or other wild type enzymes may contribute to resistance of kinase inhibitors more broadly.»

As the name suggests, kinase inhibitors interrupt the function of kinases — a particular type of enzyme — and effectively shut down the activity of proteins that contribute to cancer.

The researchers, including scientists from pharmaceutical company AstraZeneca, report in an advanced online publication in Nature Medicine on May 4, that their findings indicate «an underappreciated genomic heterogeneity» in mechanisms of resistance to tyrosine kinase inhibitor (TKI) drugs that target the Epidermal Growth Factor Receptor (EGFR) mutation that drive some cases of non-small cell lung cancer (NSCLC).

Focusing on a particular group of enzyme - blocking compounds called protein kinase inhibitors, they identified 31 compounds that inhibit malaria growth without harming the host.

Many kinase inhibitors possess axes of chirality that are freely spinning.

In practice, this means that when medicinal chemists discover a promising kinase inhibitor that exists as two interchanging arrangements, they actually have two different inhibitors.

This review focuses on kinase inhibitors that are in the clinic or in clinical trials and for which structural information is available.

But whether p38 MAP kinase inhibitors could be used to treat arthritis in humans is unclear, she says.

A class of therapeutic drugs known as protein kinase inhibitors has in the past decade become a powerful weapon in the fight against various life - threatening diseases, including certain types of leukemia, lung cancer, kidney cancer and squamous cell cancer of the head and neck.

These therapies, the first an antibody and the second of a class called tyrosine kinase inhibitors (TKIs), reduce the ability of a target gene to manufacture the protein it encodes.

Duke University assistant professor Emily Derbyshire and colleagues identified more than 30 enzyme - blocking molecules, called protein kinase inhibitors, that curb malaria before symptoms start.

Rho - kinase inhibitor Y - 27632 (ROCKi) is a potential drug molecule, which has been reported to support the gene expressions typical for the chondrocytes, thus restricting their phenotypic conversion to fibroblastic cells upon the cellular expansion.

Rho - kinase inhibitor Y - 27632 and hypoxia synergistically enhance chondrocytic phenotype and change the S100 protein profile in human chondrosarcoma cells

Rho - kinase inhibitor treatment increased the cellular proliferation up to twofold during the first 12 h, and a wound model based migration assay showed 50 % faster filling of the mechanically generated wound area.

The enzymes that phosphorylate proteins are called kinases, and many new cancer drugs are kinase inhibitors.

And within one of these kinase inhibitor libraries, the Colorado group found the PBK inhibitor HITOPK32.

Rho - kinase inhibitor Y - 27632 increases cellular proliferation and migration in human foreskin fibroblast cells